Apotex Health Corp.
32.84
CAD
-0.38
(-1.14%)
ISIN
CA03772D1015
CUSIP
03772D101
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CAD
•
in mil. unless spec.Working Capital
CAD
•
in mil. unless spec.Growth Rates
CAD
•
in mil. unless spec.Quarterly Revenue
CAD
•
in mil. unless spec.Quarterly Earnings Per Share
CAD
•
in mil. unless spec.Quarterly Dividends Per Share
CAD
•
in mil. unless spec.Company Description
- CEO
- Jeff Watson
- Full Time Employees
- 6,216
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 150 Signet Drive Toronto ON Canada M9L 1T9
- IPO Date
- Jun 10, 2026
- Website
- apotex.com
- Similar Companies
- Business
- Apotex Health Corp. is a fully integrated pharmaceutical healthcare company engaged in the development, manufacture, and commercialization of prescription medicines, over-the-counter products, and health-related consumer goods, with a focus on innovative therapies and access programs across global markets. The company operates through a diversified portfolio spanning branded and generic pharmaceuticals, biologics, and specialty products, supported by research and development, manufacturing, distribution, and regulatory compliance capabilities. Apotex Health Corp. maintains a vertically integrated operating model that includes active pharmaceutical ingredient (API) production, formulation development, finished dosage manufacturing, packaging, quality control, and global distribution networks. Founding year and headquarters - Founded in 1978 - Headquarters located in Toronto, Ontario, Canada Geographic footprint and subsidiaries - Geographic operations span North America, Europe, Asia, and emerging markets, with manufacturing facilities and regional offices across Canada, the United States, Europe, and Asia - Maintains subsidiaries and affiliates in multiple jurisdictions to support regulatory approvals, manufacturing, and commercial activities Core products and services (main products and services) - Prescription medicines: branded pharmaceutical products across therapeutic areas including oncology, immunology, infectious diseases, neurology, and cardiovasculars - Generic medicines: a broad portfolio of high-quality generics spanning multiple therapeutic classes for global markets - Biologics and biosimilars: biologic therapies and biosimilar products aimed at expanding patient access to essential biologics - Over-the-counter and consumer health products: non-prescription formulations and wellness products distributed through retail and healthcare channels - API and contract development/manufacturing: active pharmaceutical ingredients production and contract development/manufacturing services for third parties - Research and development: early-stage and late-stage clinical development, formulation science, and process optimization - Regulatory and quality services: regulatory affairs support, quality assurance, pharmacovigilance, and compliance management - Packaging, distribution, and supply chain services: finished product packaging, serialization, logistics, and broad distribution capabilities to global markets - Patient access and assistance programs: pricing, reimbursement navigation, patient support, and access programs to improve affordability and uptake Latest major company changes - Strategic alliances and partnerships: enters collaborations with global healthcare and pharmaceutical partners to co-develop and co-commercialize therapies, expand geographic reach, and optimize supply chains - Funding rounds and acquisitions: engages in selective acquisitions and strategic investments to bolster manufacturing capacity, diversify the product portfolio, and accelerate pipeline development - New product launches and service offerings: launches novel therapies and expands indications across key therapeutic areas; introduces new specialized manufacturing services and digital patient support platforms - Corporate restructurings and strategic shifts: reorganizations to optimize global operations, streamline R&D pipelines, and enhance manufacturing capacity for high-demand therapies - Operational changes: expands manufacturing footprint with new facilities or expansions, and implements advanced quality systems and regulatory compliance enhancements to accelerate time-to-market Industry context and segments - Industry: Pharmaceutical manufacturing and healthcare products - Segments: Branded pharmaceuticals, generics, biologics and biosimilars, consumer health, contract development and manufacturing, API production, and supply chain services Target markets and customers - Hospitals, clinics, specialty pharmacies, and large retail distributors - Pharmaceutical and biotechnology companies requiring contract development/manufacturing and API supply - Regulators and national health systems through pricing and reimbursement programs - Patients and caregivers via patient assistance and education initiatives Parent and subsidiaries - Operates as a stand-alone corporate entity with potential affiliates and wholly owned subsidiaries supporting regional operations and product lines - Maintains relationships with external contract manufacturers and suppliers to ensure scale and resilience Notes - The description reflects Apotex Health Corp. as a prominent player in global pharmaceutical manufacturing and healthcare products, articulating core products, services, geographic reach, and recent strategic movements in alignment with financial data provider-style profiles - For precise, up-to-date details on specific product brands, exact geographic listings, and the latest corporate actions, consult the company’s official disclosures and filings and recent announcements from Apotex Health Corp.
Company News
Apotex Receives Investment Grade Issuer Rating from Morningstar DBRS and Announces Amended & Restated Credit Agreement